Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Dow
Medtronic
Express Scripts
Johnson and Johnson

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Ublituximab


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Ublituximab?

Ublituximab is an investigational drug.

There have been 28 clinical trials for Ublituximab. The most recent clinical trial was a Phase 3 trial, which was initiated on January 27th 2015.

The most common disease conditions in clinical trials are Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Lymphoid, and Lymphoma. The leading clinical trial sponsors are TG Therapeutics, Inc., National Cancer Institute (NCI), and City of Hope Medical Center.

There are thirteen US patents protecting this investigational drug and two hundred and fifty-five international patents.

Recent Clinical Trials for Ublituximab
TitleSponsorPhase
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular LymphomaNational Cancer Institute (NCI)Phase 1/Phase 2
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular LymphomaCity of Hope Medical CenterPhase 1/Phase 2
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaYazeed SawalhaPhase 1

See all Ublituximab clinical trials

Clinical Trial Summary for Ublituximab

Top disease conditions for Ublituximab
Top clinical trial sponsors for Ublituximab

See all Ublituximab clinical trials

US Patents for Ublituximab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ublituximab ⤷  Sign up for a Free Trial Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN) ⤷  Sign up for a Free Trial
Ublituximab ⤷  Sign up for a Free Trial Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL) ⤷  Sign up for a Free Trial
Ublituximab ⤷  Sign up for a Free Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE) ⤷  Sign up for a Free Trial
Ublituximab ⤷  Sign up for a Free Trial Compositions and methods for inducing apoptosis UNIVERSITY OF UTAH RESEARCH FOUNDATION (Salt Lake City, GA) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ublituximab

Drugname Country Document Number Estimated Expiration Related US Patent
Ublituximab Australia AU2015341301 2034-10-30 ⤷  Sign up for a Free Trial
Ublituximab Canada CA2966038 2034-10-30 ⤷  Sign up for a Free Trial
Ublituximab China CN105566290 2034-10-30 ⤷  Sign up for a Free Trial
Ublituximab China CN111205268 2034-10-30 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Dow
Medtronic
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.